Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Catherine Thieblemont*, Yasmin H. Karimi, Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Wojciech Jurczak, Young Rok Do, Robin Gasiorowski, David John Lewis, Tae Min Kim, Marjolein van der Poel, Michelle Limei Poon, Tatyana Feldman, Kim M. Linton, Anna Sureda, Martin Hutchings, Minh H. Dinh, Nurgul Kilavuz, David SoongThomas Mark, Mariana Sacchi, Tycel Phillips, Pieternella J. Lugtenburg

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)
11 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology